HCG & Accenture Partner to Advance Cancer Research with AI

This partnership aims to utilize AI, including machine learning (ML), generative AI, and quantum computing, to improve early detection, diagnosis, and treatment of various cancer types.

HealthCare Global Enterprises (HCG) has collaborated with Accenture to enhance cancer research and care by leveraging advanced artificial intelligence (AI) technologies. 

This partnership aims to utilize AI, including machine learning (ML), generative AI, and quantum computing, to improve early detection, diagnosis, and treatment of various cancer types.

Dr B S Ajaikumar, Executive Chairman of HCG, commented, “Today, optimizing cancer care necessarily calls for tech-driven advancements in research and academics, especially for ensuring seamless, error-free data collection and streaming. Given the heterogenicity of tumor genomics and other forms of omics, AI has become integral to precise, personalized medical advancements. AI-powered innovation has activated established drugs in certain tumors, which was not the case previously.”
He added that Accenture’s deep expertise in technology and analytics, leveraging AI modelling, will help us enhance our research aimed at developing patient-centric therapies with lasting outcomes. 

This collaborative initiative, an integral part of our in-house research endeavors, is a fitting testament to our stature as a cancer care leader focused on disruptive innovation.”

AI-Driven Cancer Care

The collaboration combines Accenture’s technological expertise with HCG’s deep oncology knowledge. 

Together, the two organizations aim to analyze multi-omic patient data and molecular alterations to uncover new insights into cancer care. 

Accenture’s contribution includes advanced tools for image analysis, informatics, and novel algorithms to assess data from cancer patients, focusing on developing new drug targets, biomarkers, and treatment mechanisms. 

This project marks the first such initiative in South Asia, leveraging generative AI studios to drive innovation in cancer research.

Currently, the partnership is focused on the study of lung adenocarcinoma and head and neck cancers, with plans to expand the research to other cancer types. 

The goal is to use AI to understand the molecular signatures of these cancers, which could lead to improved prognosis and better responses to therapy.

Impact on Cancer Treatment and Precision Medicine

The partnership will contribute significantly to precision medicine, a tailored approach to treatment based on individual genetic and molecular profiles. By improving the understanding of cancer's origins, development, and symptoms, the collaboration aims to develop new algorithms for personalized care, offering more effective therapies. 

Additionally, it will optimize the efficiency of cancer care through AI, cloud computing, and machine learning.

Senthil Ramani, Global Lead of Data and AI at Accenture, said, “Next-gen computing, including generative AI, combined with deep biological and clinical expertise, can play a pivotal role in cancer research and care, addressing needs of patients and benefiting the global healthcare industry at large. Together with HCG, we are blending our global expertise in data and AI along with life sciences R&D to rapidly and accurately improve decision-making for the treatment and care for cancer patients in South Asia, and across the world.”